Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Advances in Brief

Rejection Antigen Peptides on BALB/c RL ♂ 1 Leukemia Recognized by Cytotoxic T Lymphocytes: Derivation from the Normally Untranslated 5′ Region of the c-Akt Proto-Oncogene Activated by Long Terminal Repeat

Hisashi Wada, Mitsutoshi Matsuo, Akiko Uenaka, Naoki Shimbara, Kenji Shimizu and Eiichi Nakayama
Hisashi Wada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitsutoshi Matsuo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akiko Uenaka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoki Shimbara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenji Shimizu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eiichi Nakayama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published November 1995
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Tumor antigen peptides on BALB/c leukemia RL♂1 that were recognized by cytotoxic T lymphocytes were shown to be derived from a normally unstranslated region of the akt proto-oncogene (Uenaka, A. et al., J. Exp. Med., 180: 1599, 1994). We show here that the murine leukemia virus (MuLV) long terminal repeat (LTR) was inserted directly into the exon of c-akt in RL♂1 leukemia and that transcription started from the cap site of the LTR. Translation appeared to start from the ATG codon created in the six nucleotides of unknown origin, which were inserted into the LTR/akt junction. The deduced molecular size is approximately Mr 59,000 due to the addition of 33 amino acid residues to the normally expressed c-AKT protein. Western blot analysis demonstrated the presence of Mr 59,000 molecules in an RL♂1 lysate, and their expression at about ten times the level of normal AKT molecules of Mr 56,000, which is consistent with the increased expression of akt mRNA demonstrated by Northern blot analysis. The findings show that the molecular alteration of AKT protein by insertion of MuLV LTR is the mechanism for creating rejection antigen peptides derived from the untranslated region of akt.

Footnotes

  • ↵1 This work was supported in part by a Grant-in-Aid for Cancer Research from the Japanese Ministry of Education, Science, and Culture.

  • ↵2 To whom requests for reprints should be addressed.

  • Received August 15, 1995.
  • Accepted September 21, 1995.
  • ©1995 American Association for Cancer Research.
PreviousNext
Back to top
November 1995
Volume 55, Issue 21
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Rejection Antigen Peptides on BALB/c RL ♂ 1 Leukemia Recognized by Cytotoxic T Lymphocytes: Derivation from the Normally Untranslated 5′ Region of the c-Akt Proto-Oncogene Activated by Long Terminal Repeat
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rejection Antigen Peptides on BALB/c RL ♂ 1 Leukemia Recognized by Cytotoxic T Lymphocytes: Derivation from the Normally Untranslated 5′ Region of the c-Akt Proto-Oncogene Activated by Long Terminal Repeat
Hisashi Wada, Mitsutoshi Matsuo, Akiko Uenaka, Naoki Shimbara, Kenji Shimizu and Eiichi Nakayama
Cancer Res November 1 1995 (55) (21) 4780-4783;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Rejection Antigen Peptides on BALB/c RL ♂ 1 Leukemia Recognized by Cytotoxic T Lymphocytes: Derivation from the Normally Untranslated 5′ Region of the c-Akt Proto-Oncogene Activated by Long Terminal Repeat
Hisashi Wada, Mitsutoshi Matsuo, Akiko Uenaka, Naoki Shimbara, Kenji Shimizu and Eiichi Nakayama
Cancer Res November 1 1995 (55) (21) 4780-4783;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Advances in Brief

  • Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
  • Recombinant Listeria Vaccines Containing PEST Sequences Are Potent Immune Adjuvants for the Tumor-Associated Antigen Human Papillomavirus-16 E7
  • 2-Arachidonoylglycerol
Show more Advances in Brief

Articles

  • Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
  • Recombinant Listeria Vaccines Containing PEST Sequences Are Potent Immune Adjuvants for the Tumor-Associated Antigen Human Papillomavirus-16 E7
  • 2-Arachidonoylglycerol
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement